GlassScriptPhysician profile
Fernando Xavier Castro
NPI 1518063718
$6,171.42
in general payments reported to CMS, 2019-2025
34 companies · $76.63 in 2025
The $76.63 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,599 · 2020: $508 · 2021: $63.12 · 2022: $377 · 2023: $2,056 · 2024: $490 · 2025: $76.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.00 |
| Education | $166.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $909.54 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Janssen Biotech, INC. | $579.13 | 2019-2023 | Tremfya |
| Lilly USA, LLC | $520.30 | 2019-2024 | Taltz, Olumiant |
| Abbvie INC. | $480.69 | 2019-2024 | Rinvoq, Skyrizi |
| Pfizer INC. | $403.84 | 2019-2024 | |
| Ucb, INC. | $331.37 | 2019-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $318.23 | 2019-2024 | |
| Glaxosmithkline, LLC. | $288.09 | 2019-2023 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $264.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $244.95 | 2021-2024 | Saphnelo |
| Octapharma USA, INC. | $233.56 | 2023-2024 | Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $188.19 | 2019-2023 | Rituxan, Actemra |
| E.R. Squibb & Sons, L.L.C. | $164.76 | 2019-2020 | |
| Celgene Corporation | $139.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.89 | 2019-2024 | Ofev, Cyltezo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $117.61 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $116.19 | 2021-2023 | Lupkynis |
| Fresenius Kabi USA, LLC | $94.73 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $70.47 | 2019-2024 | Strensiq |
| Genzyme Corporation | $69.49 | 2019-2023 | |
| Radius Health, INC. | $63.32 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $63.10 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.13 | 2023 | Cuvitru |
| Organon LLC | $46.73 | 2023 | Renflexis |
| Medexus Pharma, INC. | $35.43 | 2019-2020 | |
| Antares Pharma, INC. | $33.78 | 2019 | |
| Ani Pharmaceuticals, INC. | $32.45 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $29.71 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.98 | 2024 | Acthar |
| Ferring Pharmaceuticals INC. | $27.09 | 2019-2020 | |
| Ardelyx, INC. | $25.32 | 2024 | Ibsrela |
| Sobi, INC | $25.10 | 2024 | |
| Sandoz INC. | $20.71 | 2023 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.